AG真人官方

Context Therapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (鈥淐ontext鈥� or the 鈥淐ompany鈥�) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that the Company will participate in the following investor conferences:

• Cantor Global Healthcare Conference 2025
  Fireside chat: Wednesday, September 3 at 10:55 AM聽ET in New York, NY
  1x1 Meetings on September 3

• H.C. Wainwright 27^th Annual Global Investment Conference
  Fireside chat: Monday, September 8 at 3:30 PM ET in New York, NY
  1x1 Meetings on September 8

For additional information or to request a meeting with Context鈥檚 management team during these events, please contact your conference representative or .

About Context Therapeutics^庐
Context Therapeutics Inc. (Nasdaq: CNTX)聽is a biopharmaceutical company advancing T cell engaging (鈥淭CE鈥�) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit聽聽or follow the Company on聽 (蹿辞谤尘别谤濒测听罢飞颈迟迟别谤)听补苍诲听.

Forward-looking Statements
This press release contains 鈥渇orward-looking statements鈥� that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渆xpect,鈥� 鈥渁nticipate,鈥� 鈥渓ook forward,鈥� 鈥減lan,鈥� 鈥渋ntend,鈥� and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company and its employees to participate in and present at conferences, (ii) the potential benefits, characteristics, and side effect profile of our product candidates, and (iii) the likelihood data will support future development. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the聽U.S. Securities and Exchange Commission, including the section titled 鈥淩isk Factors鈥� contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics